The Woodlands Allergy Center, Anna George MD

12/06/2025

We are so happy to hear this!

Whataburger fan returns after 10 years of food allergiesAfter living for 10 years with food allergies, Aaron Powers from Houston, Texas, was finally cleared to start eating things he used to love. His first stop? Whataburger, of course. Aaron used to be able to eat whatever he wanted, and he always....

12/04/2025

11/15/2025

After months of investigation, researchers confirmed that a New Jersey man died of a tickborne allergy called alpha-gal syndrome after eating a hamburger.

11/12/2025

Honoring the service and sacrifice of all those who have defended our nation in uniform.

10/31/2025

Wishing everyone a fun and safe halloween!

10/29/2025

Please note: INTERNET OUTAGE at the Creekside office with the high winds. For patients with visits today, please check-in via the link on your own device. The outage may cause longer hold times on the phone. We apologize for the inconvenience.

10/25/2025

Creekside Village Halloween Spooktacular Today!

10/22/2025

FDA approves Tezspire (Tezepelumab) as first TSLP-Targeting biologic for chronic rhinosinusitis with nasal polyps (CRSwNP)

10/21/2025

Exciting updates ahead! We’re transitioning from paper to digital intake forms to serve you better. Please bear with us as we work through the upgrade—your patience means the world to us! Thank you for your support.

Meet our new Giant Day Gecko. He is an omnivorous arboreal gecko primarily native to Madagascar and lives with 3 smaller Neon Geckos in our terrarium in College Park office.

We are dedicated to children and adults with asthma, allergies, and immunodeficiency.

10/21/2025

The 2017 national guidelines recommended introducing peanut products by 11 months for low-risk infants, and by 6 months for those at high risk.

The cumulative incidence of peanut allergy fell from 0.79% in 2015 (pre-guidelines) to 0.53% in 2017, and to 0.45% in 2019 -> for a 45% reduction compared with the pre-guidelines period.

https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2024-070516/204636

10/07/2025

FDA has approved ANZUPGO® (delgocitinib) cream, as the first topical treatment of moderate-to-severe chronic hand eczema.

FDA approves first JAK inhibitor for chronic hand eczema treatment. ANZUPGO offers new hope for adults with moderate to severe symptoms.